Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Myriad Genetics (MYGN).
Myriad Genetics, Inc. and its current and former directors and officers faced shareholder derivative complaints alleging breaches of fiduciary duties. These complaints were consolidated and a settlement has been proposed, which includes corporate governance reforms and attorney fees capped at $950,000. The settlement awaits court approval, with a hearing scheduled for August 6, 2024.
See more insights into MYGN stock on TipRanks’ Stock Analysis page.